Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Terconazole + fluconazole is a combination of two antifungal agents, each with distinct but complementary mechanisms of action. Terconazole is an imidazole derivative used topically (usually as a vaginal cream or suppository) to treat fungal and yeast infections, particularly vulvovaginal candidiasis. It works by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby stopping the growth of fungi[8][9]. Fluconazole is a triazole antifungal administered orally or intravenously for systemic and mucosal fungal infections including vaginal candidiasis. It also inhibits ergosterol synthesis in fungi by targeting the cytochrome P450 enzyme 14α-demethylase[6][7]. The combination may be considered in cases where both local and systemic treatment are desired for severe or recurrent vulvovaginal candidiasis; however, there are no widely marketed products combining these two agents into a single formulation. Both drugs are well-established treatments individually for Candida infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on terconazole + fluconazole.